About Serine/threonine-protein kinase SBK2
Serine/threonine-protein kinase SBK2 (SBK2) is a protein
from Homo sapiens identified by UniProt accession
P0C263, 348 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Serine/threonine-protein kinase SBK2 |
| UniProt accession | P0C263 |
| Gene | SBK2 |
| Organism | Homo sapiens |
| Length | 348 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.42
- plasma fibronectin deficiency · score 0.07
- isolated asymptomatic elevation of creatine phosphokinase · score 0.06
- Hereditary persistence of alpha-fetoprotein · score 0.04
- congenital lethal erythroderma · score 0.04
- Congenital deficiency in alpha-fetoprotein · score 0.03
- lean body mass · score 0.02
- neoplasm · score 0.01
- multiple sclerosis · score 0.01
- cancer · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P0C263-F1 | alphafold | PREDICTED | 89.58 | — |
Amino-acid sequence (348 residues)
MPGKQSEEGP AEAGASEDSE EEGLGGLTLE ELQQGQEAAR ALEDMMTLSA QTLVRAEVDE LYEEVRPLGQ GCYGRVLLVT HRQKGTPLAL KQLPKPRTSL RGFLYEFCVG LSLGAHSAIV TAYGIGIESA HSYSFLTEPV LHGDLMAFIQ PKVGLPQPAV HRCAAQLASA LEYIHARGLV YRDLKPENVL VCDPACRRFK LTDFGHTRPR GTLLRLAGPP IPYTAPELCA PPPLPEGLPI QPALDAWALG VLLFCLLTGY FPWDRPLAEA DPFYEDFLIW QASGQPRDRP QPWFGLAAAA DALLRGLLDP HPRRRSAVIA IREHLGRPWR QREGEAEAVG AVEEEAGQ
Explore Serine/threonine-protein kinase SBK2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets